MP66-11 CARCINOGENESIS AND BACILLUS CALMETTE-GUERIN (BCG) INTRAVESICAL TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER UNDER TRYPTOPHAN AND THYMINE SUPPLEMENTATION

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology III (MP66)1 Sep 2021MP66-11 CARCINOGENESIS AND BACILLUS CALMETTE-GUERIN (BCG) INTRAVESICAL TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER UNDER TRYPTOPHAN AND THYMINE SUPPLEMENTATION Marina Ossick, Isis Kiehl, Ana Clara Salustiano, Karen Ferrari, Giovanna Degasperi, Maria Linarelli, and Leonardo Reis Marina OssickMarina Ossick More articles by this author , Isis KiehlIsis Kiehl More articles by this author , Ana Clara SalustianoAna Clara Salustiano More articles by this author , Karen FerrariKaren Ferrari More articles by this author , Giovanna DegasperiGiovanna Degasperi More articles by this author , Maria LinarelliMaria Linarelli More articles by this author , and Leonardo ReisLeonardo Reis More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002106.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Evaluate tryptophan and thymine (TT) impact on carcinogenesis and intravesical BCG bladder cancer treatment. METHODS: After identification of tryptophan plus thymine in vitro inhibitory effect in multiple cancer cell cultures, bladder cancer animal model was induced by MNU intravesical instillations and randomized into 4 groups: Control (n=9), BCG (n=9), TT (n=7) and BCG+TT (n=8). BCG groups received intravesical 106 CFU BCG in 0.2 ml saline for 6 consecutive weeks and TT groups received 1g/kg (1:1) of TT via daily gavage. After 15 weeks of protocol, animals were euthanized and the urinary bladders submitted to histopathology, immunohistochemistry, and Western blotting. RESULTS: Urothelial cancer was identified in 100%, 85.7%, 44.5% and 37.5% of Control, TT, BCG and BCG+TT groups, respectively. Cell proliferation marked by nuclear Ki-67 was higher in the Control compared to animals in the other groups (p 0.03). BCG, TT and BCG+TT groups showed proliferative cell decline and TLR4/5 labeling increase in the urothelium. BCG decreased the urothelial VEGF labeling, even in TT association. CONCLUSIONS: Tryptophan and thymine inhibit urothelial carcinogenesis and potentiate the intravesical BCG in the treatment of bladder cancer by reducing cell proliferation and activating TLRs. Source of Funding: none © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1133-e1133 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Marina Ossick More articles by this author Isis Kiehl More articles by this author Ana Clara Salustiano More articles by this author Karen Ferrari More articles by this author Giovanna Degasperi More articles by this author Maria Linarelli More articles by this author Leonardo Reis More articles by this author Expand All Advertisement Loading ...